Clinical Trial Update: REGEnLIFE RGn530 - Feasibility Pilot [NA]

View source ↗

Summary

REGEnLIFE RGn530 feasibility pilot trial in Alzheimer's disease was terminated. No efficacy or safety results are provided in the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• REGEnLIFE RGn530

Snippet

Sponsor: University Hospital, Montpellier | Conditions: Alzheimer Disease | NA | Status: TERMINATED